Interstitial lung disease induced by alectinib (CH5424802/RO5424802)
Open Access
- 14 November 2014
- journal article
- research article
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 45 (2), 221-224
- https://doi.org/10.1093/jjco/hyu183
Abstract
A 75-year-old woman with anaplastic lymphoma kinase (ALK)-rearranged Stage IV lung adenocarcinoma was administered the selective anaplastic lymphoma kinase inhibitor, alectinib, as a third-line treatment in a Phase 1–2 study. On the 102nd day, chest computed tomography showed diffuse ground glass opacities. Laboratory data revealed high serum levels of KL-6, SP-D and lactate dehydrogenase without any clinical symptoms. There was no evidence of infection. Marked lymphocytosis was seen in bronchoalveolar lavage fluid analysis, and transbronchial lung biopsy showed mild thickening of alveolar septa and lymphocyte infiltration. Interstitial lung disease was judged to be related to alectinib based on improvements in imaging findings and serum biomarkers after discontinuation of alectinib. To our knowledge, this is the first reported case of alectinib-induced interstitial lung disease. Alectinib is a promising drug for ALK-rearranged non-small cell lung cancer. Clinical trials of this selective anaplastic lymphoma kinase inhibitor will facilitate the meticulous elucidation of its long-term safety profile.Keywords
This publication has 10 references indexed in Scilit:
- Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 studyThe Lancet Oncology, 2014
- Crizotinib versus Chemotherapy in AdvancedALK-Positive Lung CancerNew England Journal of Medicine, 2013
- CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 studyThe Lancet Oncology, 2013
- Severe Acute Interstitial Lung Disease After Crizotinib Therapy in a Patient With EML4-ALK–Positive Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2013
- Drug-Related Pneumonitis in Patients With Advanced Renal Cell Carcinoma Treated With TemsirolimusJournal of Clinical Oncology, 2011
- CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper MutantCancer Cell, 2011
- EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK InhibitorsNew England Journal of Medicine, 2010
- Noninfectious Pneumonitis after Everolimus Therapy for Advanced Renal Cell CarcinomaAmerican Journal of Respiratory and Critical Care Medicine, 2010
- Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphomaMolecular Cancer Therapeutics, 2007
- Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancerNature, 2007